Key facts from Mayne Pharma Group's half-year results

Mayne Pharma Group Limited (ASX: $MYX) has reported a net loss of $70.5 million for the half-year ended 31 December 2023. The company's revenue for the period was $187.9 million, reflecting a strong performance by the Women's Health segment, which reported revenue of $72.4 million, and the Dermatology segment, which reported revenue of $80.9 million, up over 600% on the prior comparable period. The net loss attributable to members of the company for the half-year ended 31 December 2023 was a loss of $70.5 million, compared to a net profit of $290.0 million in the prior corresponding period. The company's half-year financial report includes unaudited non-IFRS financial information, which the directors consider to be a meaningful comparison from period to period. More detailed analysis of the operating performance is included in the ASX Announcement and Results Presentation dated 26 February 2024.

Executive commentary on the half-year results

Mayne Pharma Group Limited has reported a net loss of $70.5 million for the half-year ended 31 December 2023. The company's revenue for the period was $187.9 million, reflecting a strong performance by the Women's Health segment, which reported revenue of $72.4 million, and the Dermatology segment, which reported revenue of $80.9 million, up over 600% on the prior comparable period. The net loss attributable to members of the company for the half-year ended 31 December 2023 was a loss of $70.5 million, compared to a net profit of $290.0 million in the prior corresponding period. The company's half-year financial report includes unaudited non-IFRS financial information, which the directors consider to be a meaningful comparison from period to period. More detailed analysis of the operating performance is included in the ASX Announcement and Results Presentation dated 26 February 2024.

Outlook for Mayne Pharma Group

Mayne Pharma Group Limited's half-year results reflect a strong performance by the Women's Health and Dermatology segments, with revenue of $187.9 million. The company reported a net loss of $70.5 million for the half-year ended 31 December 2023, compared to a net profit of $290.0 million in the prior corresponding period. The company's half-year financial report includes unaudited non-IFRS financial information, which the directors consider to be a meaningful comparison from period to period. The company has continued the on-market share buy-back that it commenced in May 2023, with $10.9 million outlaid during the half. Mayne Pharma Group Limited has not declared or paid any dividends for the period ended 31 December 2023. The company is subject to various legal proceedings and investigations, including drug pricing and federal health care investigations, which may affect its business, financial position, and reputation. Mayne Pharma Group Limited has not made provisions for potential damage or other remedies for legal claims against it or its subsidiaries where it currently believes that a payment is either not probable or cannot be reliably estimated.